A new press release reports, “Ciox, a leading health technology company, today announced the development of the Digital Patient Clone™, a new, research-based health data repository. Currently in limited release with select partners, the Digital Patient Clone will deliver de-identified real-world data (RWD). The data available in the Digital Patient Clone will help pharmaceutical and biotech companies employ real-world evidence (RWE) to advance their scientific and commercial agendas and bring innovative therapies to patients. Ciox’s network spans approximately 60 percent of the nation’s hospitals, so the company is well-positioned to support the delivery of high-fidelity consented data from a wide variety of structured and unstructured sources. In the life sciences market, Ciox is building a more comprehensive, effective and economical research model, powered by the rich content often buried within the unstructured data in medical records, such as physician notes and patient-reported outcomes.”
The release goes on, “Oncology researchers require broad and deep data about relevant patients to improve study recruitment, monitor safety appropriately, improve dosing and identify novel indications. Today, more than 700 research organizations have at least one therapy in late-stage development, and most of the largest pharmaceutical companies have dedicated at least one-third of their late-stage R&D activity to oncology. By giving researchers a lens into how a therapy will perform in a highly variable and uncontrolled environment, RWD helps bring more targeted drugs to market quickly and with fewer adverse events.”
Read more at Newswire.
Image used under license from Shutterstock.com